臨床検査58巻9号

2014年09月発行

今月の特集1 関節リウマチ診療の変化に対応する

今後期待される分子マーカー

著者： 田村直人¹

所属機関： ¹順天堂大学　医学部膠原病内科

ページ範囲：P.1026 - P.1032

●関節リウマチ（RA）では早期診断が重要であるが，将来的に抗環状シトルリン化ペプチド抗体（抗CCP抗体）以外の自己抗体測定が，早期あるいはpreclinicalな状態での診断に有用となる可能性がある．

●客観的な疾患活動性指標としてC反応性蛋白質（CRP）は不十分であるが，マルチバイオマーカーの測定の有用性が示されており，また関節破壊進行の予測因子であることも報告されている．

●治療薬選択のためのバイオマーカーは存在せず，今後の発見が期待される．

参考文献

1）Rhodes B, Fürnrohr BG, Vyse TJ：C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol　7：282-289，2011

2）Wagner CA, Sokolove J, Lahey LJ, et al：Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann Rheum Dis, 2014, in print

3）Shi J, Knevel R, Suwannalai P, et al：Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A　108：17372-17377，2011

4）Jiang X, Trouw LA, van Wesemael TJ, et al：Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis, 2014, in print

5）Silman AJ, Hennessy E, Ollier B：Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol　31：365-368，1992

6）Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al：Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum　48：2741-2749，2003

7）Brink M, Hansson M, Mathsson L, et al：Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum　65：899-910，2013

8）Deane KD, O’Donnell CI, Hueber W, et al：The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum　62：3161-3172，2010

9）El-Gabalawy HS, Robinson DB, Smolik I, et al：Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum　64：1720-1729，2012

10）Deane KD, El-Gabalawy H：Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol　10：212-228，2014

11）Rangel-Moreno J, Hartson L, Navarro C, et al：Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest　116：3183-3194，2006

12）Willis VC, Demoruelle MK, Derber LA, et al：Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum　65：2545-2554，2013

13）平田信太郎，田中良哉：MBDAスコアによるRA活動性評価．リウマチ科　50：618-622，2013

14）Bakker MF, Cavet G, Jacobs JW, et al：Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis　71：1692-1697，2012

15）Hirata S, Dirven L, Shen Y, et al：A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford)　52：1202-1207，2013

16）Hambardzumyan K, Bolce R, Saevarsdottir S, et al：Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis, 2014, in print

17）Urano W, Taniguchi A, Yamanaka H, et al：Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics　12：183-190，2002

18）Kung TN, Dennis J, Ma Y, et al：RFC-1 80G＞A is a genetic determinant of methotrexate efficacy in Rheumatoid Arthritis: A HuGE review and meta-analysis of observational studies. Arthritis Rheum, 2013, in print

19）Danila MI, Hughes LB, Brown EE, et al：Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis? Curr Rheumatol Rep　12：342-347，2010

20）de Rotte MC, de Jong PH, den Boer E, et al：Effect of methotrexate use and erythrocyte-methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis compared with other therapies. Arthritis Rheumatol, 2014, in print

21）Takeuchi T, Miyasaka N, Tatsuki Y, et al：Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis　70：1208-1215，2011

22）Tanino M, Matoba R, Nakamura S, et al：Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun　387：261-265，2009